Business Wire

Final results from the ProCID study of efficacy and safety of 3 different dosages of Panzyga® (NewGam) in patients with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) presented at AAN 2020


Octapharma has announced that results from the ProCID study were shared for the first time as a poster presentation during the virtual American Academy of Neurology (AAN) 2020 annual meeting. ProCID was the first prospective study to compare different maintenance doses of Panzyga® (NewGam), an intravenous immunoglobulin (IVIg) in patients with chronic inflammatory demyelinating polyneuropathy (CIDP).

IVIg is the most common first-line therapy for patients with CIDP, a rare autoimmune-mediated polyneuropathy. The standard treatment regimen is a 2.0 g/kg loading dose followed by a 1.0 g/kg maintenance dose every three weeks. Guidelines recommend titrating IVIg maintenance dose and frequency to suit the individual patients’ needs1. However, most clinical studies have assessed only a single maintenance dose of IVIg and only one small prospective, randomised study to date has compared different doses2. Studies of IVIg maintenance doses beyond the standard 1.0 g/kg are therefore of great clinical interest. The ProCID study assessed the efficacy of Panzyga® in this large study of IVIg in CIPD patients: It is the largest clinical trial to have analysed a lower and a higher maintenance dose of IVIG compared to the 1 g/kg standard dose.

The ProCID study was a prospective, double-blind, randomised, multi-centre phase III study that assessed the efficacy and safety of Panzyga® in patients with CIDP and compared two different maintenance dosages of Panzyga® (a higher one of 2.0 g/kg and a lower one of 0.5 g/kg) with the standard dosing scheme of 1.0 g/kg every 3 weeks. The study enrolled 142 patients from 25 sites in 9 countries. The results of the study confirmed the efficacy of Panzyga® in adults with CIDP at the standard dose of 1.0 g/kg every 3 weeks. Almost 80% (55/69) of patients responded to treatment with a decrease of at least 1 point in the adjusted inflammatory neuropathy cause and treatment (INCAT) disability score by the end of the 24-week treatment period. Results also suggested a dose response with a greater proportion of patients responding with increasing doses of Panzyga®: 64.7%, 79.7% and 91.7% of patients were considered responders on the adjusted INCAT score in the 0.5, 1.0 and 2.0 g/kg treatment groups, respectively. Panzyga® was generally well tolerated.

Professor David Cornblath of John Hopkins University School of Medicine, presenting author of the poster and Chair of the ProCID Study Steering Committee, commented “In this large study comparing 3 different IVIg maintenance doses in CIDP, the results suggest a dose-dependent response to Panzyga®. This dose response is observed in the primary as well as the secondary efficacy endpoints. The results are important to clinicians as they consider the best dose of IVIg to maximize patient benefit. I am certain this study will be widely discussed.

Olaf Walter, Board Member at Octapharma, added “the new insights that ProCID provided on different dosing regimens will help doctors to tailor better the CIDP therapies to the patients’ individual needs. We are proud to contribute to expanding treatment options for this patient group as part of our mission to improve the lives of patients.

The results of the ProCID study confirm the efficacy and safety of Panzyga® in patients with CIDP and suggest that the standard dosing regimen may not be optimal in some patients. The important results from this study will help doctors determine the right dose for their patients.

About CIDP

CIDP is an immune mediated neuropathy characterised by progressive weakness and impaired sensory function in the limbs. In patients with CIDP, only 20-30% are cured while the rest require long term treatment3. Many suffer permanent disability. In addition to IVIg, other front-line therapy options include corticosteroids and plasma exchange.

About Panzyga®

Panzyga® is a 10% human normal immunoglobulin solution ready for intravenous administration. The manufacturing process achieves a significant viral reduction through a combination of three dedicated manufacturing process steps: solvent/detergent treatment, ion-exchange chromatography and nanofiltration (20 nm) and thus complies with the latest international consensus on best practices for viral safety. Panzyga® is approved for use in treatment of primary immunodeficiency and idiopathic thrombocytopenic purpura in several countries.

About the ProCID study

The ProCID study (NCT02638207) was a prospective, double-blind, randomized, parallel group, multi-center phase III study which investigated the efficacy and safety of Panzyga® in patients with CIDP at the standard maintenance dose (1.0 g/kg) and at a lower (0.5 g/kg) and a higher (2.0 g/kg) maintenance dose every 3 weeks for up to 24 weeks. The study was conducted across 25 sites and a total of 142 patients were enrolled and treated with Panzyga®.

About Octapharma

Headquartered in Lachen, Switzerland, Octapharma is one of the largest human protein manufacturers in the world, developing and producing human proteins from human plasma and human cell lines.

Octapharma employs more than 10,000 people worldwide to support the treatment of patients in 118 countries with products across three therapeutic areas: Hematology, Immunotherapy, and Critical Care.

Octapharma has seven R&D sites and six state-of-the-art manufacturing facilities in Austria, France, Germany, Mexico and Sweden, with a combined capacity of approximately 8 million litres of plasma per annum.

In addition, Octapharma operates more than 140 plasma donation centres across Europe and the US.

1 van den Bergh PYK, Hadden RDM, Bouche P, et al. European Federation of Neurological Societies/Peripheral Nerve Society guideline on management of chronic inflammatory demyelinating polyradiculoneuropathy: report of a joint task force of the European Federation of Neurological Societies and the Peripheral Nerve Society - first revision. Eur J Neurol 2010; 17: 356–63.
2 Kubori T, Mezaki T, Kaji R, et al. The clinical usefulness of high-dose intravenous immunoglobulin therapy for chronic inflammatory demyelinating polyneuropathy and multifocal motor neuropathy. No To Shinkei 1999; 51: 127–35.
3 Gorson KC, van Schaik IN, Merkies ISJ, et al. Chronic inflammatory demyelinating polyneuropathy disease activity status, Recommendations for clinical research standards and use in clinical practice. J Peripher Nerv Syst 2010;15:326–33.

Contact information

Macarena Guillamón
Corporate Communications
Tel: +41554512121

About Business Wire

Business Wire
Business Wire

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Spirit of Wipro Run Brings Together Thousands of Participants Globally27.9.2020 08:52:00 CESTPress release

Wipro Limited (NYSE: WIT, BSE: 507685, NSE: WIPRO), a leading global information technology, consulting and business process services company, today organized the 15th edition of the ‘Spirit of Wipro’ (SOW) Run globally with thousands of participants across 35 countries, running separately, yet together in spirit, at a time of their choosing. The theme for this year’s Run was “United. Unstoppable”, which celebrated camaraderie, resilience and a shared sense of community among several thousands of Wipro employees, their friends and families, alumni, customers, partners and suppliers. The SOW Run is an annual, global tradition at Wipro and has been held every year since its inception. This year too, the Run was organized on schedule despite the pandemic induced constraints. The runners strictly adhered to the local COVID-19 guidelines and safety protocols in various countries while participating in the event. Commenting on the Run, Thierry Delaporte, Chief Executive Officer and Managing

BCG Collaborates with Tencent Marketing Insight to Release 2020 BCG x Tencent Digital Luxury Report25.9.2020 12:21:00 CESTPress release

Since early 2020 when the COVID-19 pandemic broke out worldwide, the luxury market has been hit hard and is expected to decline 25% to 45% compared to the previous year. The Chinese luxury market, however, which has benefitted from successful domestic control of the pandemic and has taken the lead in recovery against a depressed global market environment, is forecast to grow from 20% to 30% in the whole year of 2020. Thanks to its stunning market performance, China has become the main battleground of each major luxury brand. In was in this environment that Boston Consulting Group (BCG) joined hands with Tencent Marketing Insight (TMI) to release the 2020 BCG x Tencent Digital Luxury Report, drawing on deep insights into post COVID-19 trends in the luxury market and consumers based on BCG and TMI’s quantitative consumer research and industry experience, as well as TMI’s marketing and big data capabilities. Crystal Hao, Managing Director & Partner of BCG said, “The luxury market in China

U.S. MRTP Authorization Pathway Explored in PMI’s Latest Scientific Update25.9.2020 12:15:00 CESTPress release

Philip Morris International (PMI) (NYSE: PM) has released the 11th edition of its Scientific Update, a regularly issued publication on its research efforts to develop and scientifically assess a range of smoke-free alternatives to cigarettes. The latest edition features an overview of the historic decision made by the U.S. Food and Drug Administration (FDA) to authorize the marketing of the IQOS Tobacco Heating System with reduced exposure information. The Scientific Update explains the various MRTP decisions under U.S. law; the steps, processes, and timeline PMI undertook; and the ongoing post-market surveillance and studies that will monitor the impact of the orders on consumer perceptions, behavior, and health. “The FDA undertook a scientific and regulatory evaluation of IQOS and determined that it is ‘appropriate for the promotion of public health’” said Dr. Gizelle Baker, director of Global Scientific Engagement at PMI. “In this edition of our Scientific Update, we describe how th

Palladio Completes $20 Million Series B Financing25.9.2020 12:09:00 CESTPress release

Palladio Biosciences, Inc. (Palladio), a privately-held, clinical stage biopharmaceutical company developing medicines for orphan diseases of the kidney, announced today the completion of a $20 million Series B investment. The financing was led by new investor, Samsara BioCapital, with participation from new investor, the Roche Venture Fund and existing investors, Medicxi and Osage University Partners. Proceeds from the financing will fund Palladio’s Phase 3 ALERT Study and advance operations. Srinivas Akkaraju M.D, Ph.D, Managing General Partner of Samsara BioCapital, stated, "We are very excited about our investment in Palladio to support the development of lixivaptan, a drug that has the potential to deliver a meaningful therapeutic advancement in the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD). The ALERT Study is an important step in assessing the safety differential of lixivaptan.” “We are very pleased that Samsara and the Roche Venture Fund recognize the opp

Ant Group Launches “Trusple,” an AntChain-Powered Global Trade and Financial Services Platform for SMEs and Financial Institutions25.9.2020 09:54:00 CESTPress release

Ant Group, a leading provider in the development of open platforms for technology-driven inclusive financial services, and the parent company of China’s largest digital payment platform Alipay, today unveiled Trusple, an international trade and financial service platform powered by AntChain, the company’s blockchain-based technology solutions. Trusple aims to make it easier and less costly for all participants – especially Small-to-Medium Enterprises (SMEs) – to sell their products and services to customers around the world. It also reduces costs for financial institutions so they can better serve SMEs in need. This press release features multimedia. View the full release here: (Photo: Business Wire) Based on the concept of “Trust Made Simple,” Trusple works by generating a smart contract once a buyer and a seller upload a trading order on the platform. As the order is executed, the smart contract is automatically updated with k

Ipsen Appoints Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer25.9.2020 07:00:00 CESTPress release

Regulatory News: This press release features multimedia. View the full release here: Philippe Lopes-Fernandes, Executive Vice President, Chief Business Officer, Ipsen (Photo: Business Wire) Ipsen (Euronext: IPN; ADR: IPSEY) today announced the appointment of Philippe Lopes-Fernandes as Executive Vice President, Chief Business Officer, effective 1 October 2020. Based in Cambridge, Massachusetts, USA, he will be responsible for business development and alliance management, reporting directly to David Loew, CEO, Ipsen. Philippe will serve on the Executive Leadership Team. “As Chief Business Officer, Philippe will play a crucial role in our external innovation strategy. The ELT and I are delighted to welcome Philippe to Ipsen and look forward to working closely with him. His extensive and impressive track record in international business development, his outstanding reputation and his ability to work closely with the scientific comm

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom